The Silent War for the Oral GLP-1 Crown: Why Patents Matter Most

DALLAS, TX – February 26, 2026 – The pharmaceutical industry's frenzied race to develop a blockbuster oral weight-loss pill has entered a new, far more complex phase. As dozens of companies close in on drugs that deliver similar clinical results, a groundbreaking new report reveals the ultimate winner may not be decided in the lab or the clinic, but in the arcane world of intellectual property law.

PatentVest, an IP intelligence firm, today released its comprehensive analysis, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron,” which maps the patent landscape of a market poised to explode. While injectable GLP-1 drugs like Ozempic and Mounjaro have already built a staggering $71 billion market, they reach less than 5% of the eligible patient population. The true prize—the remaining 95%—is expected to be unlocked by the convenience of a daily pill, and some 50 oral programs are now vying for that dominance.

From Efficacy to Exclusivity: The New Competitive Moat

For years, the primary goal was clear: develop an oral GLP-1 drug that could replicate the impressive 15-25% weight loss of its injectable predecessors. Now, as leading candidates from Eli Lilly, Structure Therapeutics, and others begin to show converging efficacy in the 12-16% weight-loss range, the competitive goalposts are shifting dramatically.

The PatentVest report, which dissects over 1,200 patent documents across 26 clinical-stage programs, argues that long-term market leadership will depend less on marginal differences in weight-loss percentages and more on the strength and breadth of a company's patent portfolio. The findings reveal what the firm calls “dramatic disparities” in patent depth between programs at similar stages of development, creating hidden vulnerabilities and advantages that could define the market for decades.

“When multiple drugs deliver similar weight-loss results, the competitive moat shifts beneath the surface,” said Javier Chamorro, Chief Operating Officer of PatentVest, in the company's announcement. “The difference between a broad genus claim and a narrow composition patent can determine who owns this market for the next twenty years.”

This new battlefield is one of legal strategy, where companies are building “patent thickets”—dense, overlapping layers of intellectual property protection. These include not only the core composition-of-matter patents on the drug molecule itself but also secondary patents covering manufacturing processes, specific formulations, and new methods of use, such as treating related conditions like cardiovascular disease or MASH.

Navigating the Patent Minefield Ahead of a Looming Cliff

The strategic urgency is amplified by the looming patent expirations of today's biggest blockbusters. The main patent for Novo Nordisk’s semaglutide (the active ingredient in Ozempic and Rybelsus) is set to expire as early as 2026 in some countries and around 2031 in the United States. Eli Lilly’s tirzepatide (Mounjaro and Zepbound) faces its own cliff in 2036. When these patents fall, the market will open to a flood of lower-cost generic competitors, potentially erasing billions in revenue overnight.

To defend their franchises, both pharmaceutical giants have been aggressively filing follow-on patents. Novo Nordisk has secured dozens of patents extending protection for semaglutide in various forms until as late as 2042, while Eli Lilly has constructed a similar fortress around tirzepatide. This complex web of IP forces any potential generic manufacturer to navigate a legal minefield, delaying their entry long after the core compound is off-patent.

For the new wave of oral small-molecule developers, establishing this kind of robust, multi-layered protection from the outset is critical. Unlike complex biologic drugs, small-molecule pills like Lilly’s orforglipron can be more easily replicated by generic manufacturers. Without a formidable patent strategy, a company could find its multi-billion-dollar investment eroded by generic pressure shortly after launch.

A Surge in Deal-Making and the Hunt for Unpartnered Gems

The high stakes have ignited a firestorm of investment and acquisition activity. More than $47 billion in GLP-1-related deal value has been committed since 2023. In 2023, Roche paid $2.7 billion upfront to acquire Carmot Therapeutics for its portfolio of incretin therapies, including an oral GLP-1 candidate. AstraZeneca followed with a deal worth over $2 billion for the rights to Eccogene’s oral GLP-1 agonist.

Despite this frenzy, the PatentVest report highlights a crucial fact: most oral programs remain unpartnered. This creates a high-stakes environment where pharmaceutical giants are scrutinizing smaller biotechs not just for their clinical data, but for the defensibility of their intellectual property. Companies like Structure Therapeutics and Viking Therapeutics, with promising oral candidates, are now viewed as prime acquisition targets, with their value hinging as much on their patent filings as their Phase II results.

This intense focus on IP is driving a new kind of M&A calculus. Acquirers are looking for assets that offer not just a novel molecule, but a clear, defensible path to long-term market exclusivity. This includes unique delivery technologies, like those being pursued in Novo Nordisk's $2.1 billion partnership with Vivtex, or next-generation mechanisms such as dual or triple-agonist drugs that target multiple metabolic pathways simultaneously.

The race is global, with companies like China’s Jiangsu Hengrui and MindRank advancing their own oral GLP-1 candidates into late-stage trials, adding another layer of competitive complexity. As the pipeline of potential treatments grows, the ability to secure a lasting competitive advantage through intellectual property will be the ultimate factor that separates fleeting successes from enduring franchises in the next chapter of metabolic medicine.